(Q53859028)

21 May 2018

title

Basiliximab in lung transplantation: preliminary experience. (English)

1 reference

21 May 2018

1 reference

M de la Torre

1

1 reference

21 May 2018

E Peña

2

1 reference

21 May 2018

M Calvin

3

1 reference

21 May 2018

C Miguélez

4

1 reference

21 May 2018

D González

5

1 reference

21 May 2018

R Fernández

6

1 reference

21 May 2018

F Molina

7

1 reference

21 May 2018

J M Borro

8

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 April 2005

1 reference

21 May 2018

Transplantation Proceedings

published in

1 reference

21 May 2018

volume

37

1 reference

21 May 2018

issue

3

1 reference

21 May 2018

page(s)

1534-1536

1 reference

21 May 2018

Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen usi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

Basiliximab in the therapy of acute rejection after organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.02.026

10.1016/J.TRANSPROCEED.2005.02.026

7 January 2021

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018